----
All Shareholders
Shareholder Type
- Public and others46.36%
- VC/PE firms32.30%
- Hedge funds8.70%
- Private companies6.05%
- Others6.58%
Major Shareholders
| Shareholder | |||||
|---|---|---|---|---|---|
OrbiMed Advisors LLC | 10.97% | 6.89M | -- | +6.89M | |
Westlake Village BioPartners | 10.11% | 6.35M | -- | +6.35M | |
Redmile Group, LLC | 8.70% | 5.46M | -- | +5.46M | |
Lsp 7 Cooperatief U.A. | 6.05% | 3.80M | -- | +3.80M | |
EQT Life Sciences | 6.05% | 3.80M | -- | +3.80M | |
New Leaf Venture Partners, LLC | 5.18% | 3.25M | -- | +3.25M | |
Sanofi | 3.92% | 2.46M | -- | +2.46M | |
Quehuong DongPresident, CEO & Director | 0.73% | 455.48K | -- | +455.48K | |
T. Rowe Price Group, Inc. | 0.67% | 417.57K | -- | +417.57K | |
Nancy StaglianoIndependent Chair | 0.41% | 255.64K | -- | +255.64K | |
Vanguard Capital Management, LLC | 0.36% | 225.16K | -- | +225.16K | |
Columbia Management Investment Advisers, LLC | 0.20% | 127.94K | -- | +127.94K | |
Graham ParryChief Scientific Officer | 0.14% | 85.50K | -- | +85.50K | |
Gary KoeChief Technology Officer | 0.10% | 63.66K | -- | +63.66K | |
Y-Intercept (Hong Kong) Limited | 0.03% | 21.10K | -- | +21.10K | |
Vanguard Portfolio Management, LLC | 0.03% | 18.21K | -- | +18.21K | |
Matthew FustIndependent Director | 0.00% | 0.00 | -- | +0 | |
Kim-Hien DaoChief Medical Officer | 0.00% | 0.00 | -- | +0 |
